{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T11:23:20Z","timestamp":1769426600208,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Queen Elizabeth Hospital Birmingham Charities","award":["17-3-728"],"award-info":[{"award-number":["17-3-728"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clon.2018.01.015","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T09:28:57Z","timestamp":1519982937000},"page":"366-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Feasibility of Dose-escalated Hypofractionated Chemoradiation in Human Papilloma Virus-negative or Smoking-associated Oropharyngeal Cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"S.","family":"Meade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gaunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Harrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cashmore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Wagstaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Babrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mehanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sanghera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2018.01.015_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.clon.2018.01.015_bib2","doi-asserted-by":"crossref","unstructured":"Mehanna H, Dunn J, McConkey C, Hartley A, Robinson M, Kong A, et al. De-ESCALaTE HPV: determination of epidermal growth factor receptor-inhibitor (cetuximab) versus standard chemotherapy (cisplatin) early and late toxicity events in human papillomavirus-positive oropharyngeal squamous cell carcinoma. deescalate@warwick.ac.uk. ISRCTN identifier ISRCTN33522080. https:\/\/doi.org\/10.1186\/ISRCTN33522080.","DOI":"10.1186\/ISRCTN33522080"},{"key":"10.1016\/j.clon.2018.01.015_bib3","unstructured":"Trotti A, Gillison M. RTOG 1016 phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer. www.rtog.org. ClinicalTrials.gov identifier NCT01302834."},{"key":"10.1016\/j.clon.2018.01.015_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(06)69121-6","article-title":"Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis","volume":"368","author":"Bourhis","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.01.015_bib6","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(03)14361-9","article-title":"Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial","volume":"362","author":"Overgaard","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2018.01.015_bib7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clon.2006.09.008","article-title":"Is there an optimum overall time for head and neck radiotherapy? A review with new modelling","volume":"19","author":"Fowler","year":"2007","journal-title":"Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2018.01.015_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/02841860802372272","article-title":"IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult","volume":"48","author":"Ho","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2003.09.011","article-title":"CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines","volume":"69","author":"Gr\u00e9goire","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib11","doi-asserted-by":"crossref","unstructured":"Mehanna H. A trial looking at different treatments for\u00a0people\u00a0with oropharyngeal cancer (CompARE). http:\/\/www.cancerresearchuk.org\/about-cancer\/find-a-clinical-trial. ISRCTN identifier ISRCTN41478539. https:\/\/doi.org\/10.1186\/ISRCTN41478539.","DOI":"10.1186\/ISRCTN41478539"},{"key":"10.1016\/j.clon.2018.01.015_bib12","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa1514493","article-title":"PET-CT surveillance versus neck dissection in advanced head and neck cancer","volume":"374","author":"Mehanna","year":"2016","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.clon.2018.01.015_bib13","doi-asserted-by":"crossref","unstructured":"Nutting C. A randomised, multicentre accelerated radiotherapy study of dose escalated intensity-modulated radiotherapy versus standard dose intensity-modulated radiotherapy in patients receiving treatment for locally advanced laryngeal and hypopharyngeal cancers. http:\/\/rttrialsqa.dnsalias.org\/. ISRCTN identifier ISRCTN01483375. https:\/\/doi.org\/10.1186\/ISRCTN01483375.","DOI":"10.1186\/ISRCTN01483375"},{"issue":"6","key":"10.1016\/j.clon.2018.01.015_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clon.2014.03.003","article-title":"NIMRAD \u2013 a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer","volume":"26","author":"Thomson","year":"2014","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.ijrobp.2009.04.011","article-title":"Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22)","volume":"76","author":"Eisbruch","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2018.01.015_bib16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ijrobp.2012.06.037","article-title":"Radiation-free weekend rescued! Continuous Accelerated irradiation of 7-days per week is equal to accelerated fractionation with concomitant boost of 7 fractions in 5-days per week: report on phase 3 clinical trial in head-and-neck cancer patients","volume":"85","author":"Skladowski","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2018.01.015_bib17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.clon.2007.04.005","article-title":"Radiobiological modelling of UK head and neck schedules \u2013 calculation errors","volume":"19","author":"Ho","year":"2007","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.radonc.2007.07.011","article-title":"A\u00a0phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer","volume":"85","author":"Guerrero Urbano","year":"2007","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.clon.2018.01.015_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/0284186X.2014.958528","article-title":"Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma","volume":"54","author":"Thomson","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0360-3016(99)00101-7","article-title":"Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy","volume":"45","author":"Butler","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.clon.2018.01.015_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.otohns.2006.10.044","article-title":"Accelerated radiotherapy with simultaneous integrated boost fractionation and intensity-modulated radiotherapy for advanced head and neck cancer","volume":"136","author":"Schwartz","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.clon.2018.01.015_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clon.2005.08.014","article-title":"Carboplatin and hypofractionated accelerated radiotherapy: a dose escalation study of an outpatient chemoradiation schedule for squamous cell carcinoma of the head and neck","volume":"18","author":"Madhava","year":"2006","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib23","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.ijrobp.2006.11.015","article-title":"Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck","volume":"67","author":"Sanghera","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2018.01.015_bib24","article-title":"Four week hypofractionated accelerated intensity modulated radiotherapy and synchronous carboplatin or cetuximab in biologically staged oropharyngeal carcinoma","volume":"2","author":"Benghiat","year":"2014","journal-title":"Cancer Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.clon.2018.01.015_bib25","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1200\/jco.2010.28.15_suppl.5507","article-title":"A\u00a0phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome","volume":"28","author":"Ang","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2018.01.015_bib26","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ijrobp.2008.06.836","article-title":"Accelerated versus conventional radiotherapy with concomitant chemotherapy in locally advanced head and neck carcinomas: results of a phase III randomised trial (GORTEC 99-02)","volume":"72","author":"Bourhis","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2018.01.015_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijrobp.2012.11.023","article-title":"Revising the radiobiological model of synchronous chemotherapy in head-and-neck cancer: a new analysis examining reduced weighting of accelerated repopulation","volume":"86","author":"Meade","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2018.01.015_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1017\/S1460396907006231","article-title":"Gap compensation during accelerated hypofractionated radiotherapy in head and neck cancer","volume":"7","author":"Sanghera","year":"2008","journal-title":"J\u00a0Radiother Prac"},{"key":"10.1016\/j.clon.2018.01.015_bib29","unstructured":"Zubizaretta E, CRP on resource sparing curative radiotherapy for locally advanced squamous cell cancer of the head and neck (the HYPNO trial). http:\/\/www-naweb.iaea.org\/nahu\/ARBR\/documents\/CRP_E33035_300614.pdf. ClinicalTrials.gov identifier NCT02765503."},{"issue":"11","key":"10.1016\/j.clon.2018.01.015_bib30","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clon.2010.07.015","article-title":"Hypofractionated accelerated radiotherapy with concurrent carboplatin for locally advanced squamous cell carcinoma of the head and neck","volume":"23","author":"Chan","year":"2011","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0167-8140(99)00107-3","article-title":"Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer?","volume":"52","author":"Denham","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0167-8140(00)00139-0","article-title":"Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity","volume":"55","author":"Skladowski","year":"2000","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.clon.2018.01.015_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.radonc.2016.06.015","article-title":"A\u00a0randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer","volume":"122","author":"Wong","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tipsro.2017.02.001","article-title":"A\u00a0prospective comparison of common toxicity criteria adverse events Version 3 and 4 in assessing oral mucositis for oral and oropharyngeal carcinoma","volume":"1","author":"Hickman","year":"2017","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clon.2018.01.015_bib36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2012.02.010","article-title":"Heterogeneity in head and neck IMRT target design and clinical practice","volume":"103","author":"Hong","year":"2012","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.clon.2018.01.015_bib37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.clon.2011.07.006","article-title":"Variation in volume definition between UK head and neck oncologists treating oropharyngeal carcinoma","volume":"23","author":"Pettit","year":"2011","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial","volume":"12","author":"Nutting","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib39","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.clon.2012.09.004","volume":"24","author":"Chatterjee","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clon.2018.01.015_bib40","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1634\/theoncologist.2017-0015","article-title":"Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data","volume":"22","author":"Szturz","year":"2017","journal-title":"Oncologist"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655518300463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655518300463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:44:52Z","timestamp":1760543092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655518300463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0936655518300463"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2018.01.015","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of Dose-escalated Hypofractionated Chemoradiation in Human Papilloma Virus-negative or Smoking-associated Oropharyngeal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2018.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}